# A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX

> **NCT00494221** · PHASE1,PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 172 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** AZD2171
- **DRUG:** FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- **DRUG:** Placebo Cediranib

## Key facts

- **NCT ID:** NCT00494221
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-10
- **Final completion:** 2012-08
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2014-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00494221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00494221, "A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00494221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*